PMEL and melanoma: In melanoma, CheckMate 067 demonstrated a 20.9 month overall survival benefit with combined first‐line ipilimumab and nivolumab compared to ipilimumab alone, which had previously been demonstrated to be superior to dacarbazine or gp100 vaccine in the first line [1, 6, 27].